Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QTRX Stock Forecast 2026-2027
$3.96
Current Price
$192.19M
Market Cap
Buy 0
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to QTRX Price Targets
+26.3%
To High Target of $5.00
+1.0%
To Median Target of $4.00
+1.0%
To Low Target of $4.00
QTRX Price Momentum
+2.1%
1 Week Change
+37.5%
1 Month Change
-28.1%
1 Year Change
-37.7%
Year-to-Date Change
-54.8%
From 52W High of $8.77
+65.3%
From 52W Low of $2.40
📊 TOP ANALYST CALLS
Did QTRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Quanterix is one of their latest high-conviction picks.
Latest QTRX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, QTRX has a neutral consensus with a median price target of $4.00 (ranging from $4.00 to $5.00). The overall analyst rating is Buy (6.0/10). Currently trading at $3.96, the median forecast implies a 1.0% upside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Dan Brennan at TD Cowen, suggesting a 1.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QTRX Analyst Ratings
0
Buy
3
Hold
0
Sell
QTRX Price Target Range
Low
$4.00
Average
$4.00
High
$5.00
Current: $3.96
Latest QTRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QTRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2026 | TD Cowen | Dan Brennan | Hold | Maintains | $4.00 |
| Apr 20, 2026 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Dec 22, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Aug 11, 2025 | Canaccord Genuity | Hold | Downgrade | $N/A | |
| May 13, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 30, 2025 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Mar 25, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Mar 18, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 13, 2024 | TD Cowen | Hold | Maintains | $N/A | |
| Aug 12, 2024 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Aug 9, 2024 | TD Cowen | Hold | Maintains | $N/A | |
| Jul 9, 2024 | Goldman Sachs | Buy | Maintains | $N/A | |
| Apr 29, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 4, 2024 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Sep 28, 2023 | Goldman Sachs | Buy | Maintains | $N/A | |
| Sep 27, 2023 | Goldman Sachs | Buy | Maintains | $N/A | |
| Sep 25, 2023 | Canaccord Genuity | Buy | Upgrade | $N/A | |
| Aug 9, 2023 | Goldman Sachs | Buy | Maintains | $N/A | |
| May 24, 2023 | Goldman Sachs | Buy | Maintains | $N/A | |
| May 23, 2023 | Goldman Sachs | Buy | Upgrade | $N/A |
Quanterix Corporation (QTRX) Competitors
The following stocks are similar to Quanterix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
QTRX
Quanterix
mkt cap
182.77M
Quanterix Corporation (QTRX) Financial Data
Quanterix Corporation has a market capitalization of $192.19M with a P/E ratio of -1.6x. The company generates $144.98M in trailing twelve-month revenue with a -71.9% profit margin.
Revenue growth is +20.1% quarter-over-quarter, while maintaining an operating margin of -59.1% and return on equity of -34.8%.
Valuation Metrics
Market Cap
$192.19M
Enterprise Value
$118.84M
P/E Ratio
-1.6x
PEG Ratio
0.1x
Price/Sales
1.3x
Growth & Margins
Revenue Growth (YoY)
+20.1%
Gross Margin
+42.7%
Operating Margin
-59.1%
Net Margin
-71.9%
EPS Growth
+20.3%
Financial Health
Cash/Price Ratio
+53.2%
Current Ratio
3.7x
Debt/Equity
12.5x
ROE
-34.8%
ROA
-13.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Quanterix Corporation (QTRX) Business Model
About Quanterix Corporation
What They Do
Develops ultra-sensitive digital immunoassay technology.
Business Model
Quanterix generates revenue by providing advanced diagnostic tools and technology platforms, specifically its Simoa platform, to researchers and clinicians in the life sciences sector. The company focuses on biomolecule detection in various diseases, facilitating early diagnosis and monitoring, which enhances the development of new therapies and personalized medicine.
Additional Information
Quanterix's technology is crucial in multiple medical fields including oncology, neurology, cardiology, and infectious diseases, offering significant advancements in how biomarkers are measured. This capability not only accelerates medical research but also improves healthcare outcomes, positioning Quanterix as a key player in the evolving landscape of life sciences.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
450
CEO
Mr. Everett V. Cunningham
Country
United States
IPO Year
2017
Website
www.quanterix.comQuanterix Corporation (QTRX) Latest News & Analysis
Latest News
Quick Summary
Quanterix Corporation (NASDAQ: QTRX) announced key milestones advancing clinical adoption of its blood-based Alzheimer's test, LucentAD® Complete, enhancing evaluation of the disease.
Why It Matters
Quanterix's advancements in blood-based Alzheimer's testing may boost market confidence and demand for its products, potentially leading to increased revenue and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Quanterix Corporation (NASDAQ: QTRX) announced inducement grants of 336,804 restricted stock units to three new employees, effective June 15, 2026.
Why It Matters
The issuance of RSUs to new employees signals confidence in growth and retention, potentially enhancing Quanterix's innovation and market position, which could impact stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Quanterix Corporation appointed Jason Faessler as CFO, effective June 22. He brings extensive finance experience in the life science tools sector to support the company's strategic goals.
Why It Matters
The appointment of Jason Faessler as CFO signals potential strategic shifts and financial management improvements at Quanterix, which could influence investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Quanterix Corporation (QTRX) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its strategies and developments in the healthcare sector.
Why It Matters
Quanterix's presentation at a major healthcare conference can signal its strategic direction, potential partnerships, and innovations, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Quanterix Corporation appointed Geoff Albrecht as SVP and General Manager of Diagnostics, aiming to enhance its growth strategy, particularly in Alzheimer's Disease Diagnostics.
Why It Matters
Geoff Albrecht's appointment signals a strategic focus on diagnostics, particularly in Alzheimer's, potentially enhancing Quanterix's growth and market positioning in healthcare innovation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Quanterix Corporation (Nasdaq: QTRX) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026. CEO Everett Cunningham will present on June 9 at 1:20 pm ET.
Why It Matters
Quanterix's participation in a major healthcare conference suggests potential visibility and interest in its innovations, possibly impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About QTRX Stock
What is Quanterix Corporation's (QTRX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Quanterix Corporation (QTRX) has a median price target of $4.00. The highest price target is $5.00 and the lowest is $4.00.
Is QTRX stock a good investment in 2027?
According to current analyst ratings, QTRX has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QTRX stock?
Wall Street analysts predict QTRX stock could reach $4.00 in the next 12 months. This represents a 1.0% increase from the current price of $3.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Quanterix Corporation's business model?
Quanterix generates revenue by providing advanced diagnostic tools and technology platforms, specifically its Simoa platform, to researchers and clinicians in the life sciences sector. The company focuses on biomolecule detection in various diseases, facilitating early diagnosis and monitoring, which enhances the development of new therapies and personalized medicine.
What is the highest forecasted price for QTRX Quanterix Corporation?
The highest price target for QTRX is $5.00 from at , which represents a 26.3% increase from the current price of $3.96.
What is the lowest forecasted price for QTRX Quanterix Corporation?
The lowest price target for QTRX is $4.00 from Dan Brennan at TD Cowen, which represents a 1.0% increase from the current price of $3.96.
What is the overall QTRX consensus from analysts for Quanterix Corporation?
The overall analyst consensus for QTRX is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are QTRX stock price projections?
Stock price projections, including those for Quanterix Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:09 AM UTC